← back to search

Martin Metz

Humboldt-Universität zu Berlin · DE
Area of research
Rheumatology · Dermatology
Research interest
Research interests include Urticaria and Related Conditions, Dermatology and Skin Diseases, Mast cells and histamine, and Coagulation, Bradykinin, Polyphosphates, and Angioedema.
h-index
86
citations
24,701
works
469
NIH funding
primary concept
email

Recent publications

Comment on ‘Patients with acute and chronic spontaneous urticaria have similar autoantibody profiles: CHAPEAU pilot study’: reply from authors
British Journal of Dermatology 2026cited by 1position: middledoi
Remibrutinib in Chronic Spontaneous Urticaria
New England Journal of Medicine 2025cited by 78position: firstdoi
Update on the Treatment of Chronic Spontaneous Urticaria
Drugs 2025cited by 29position: lastdoi
Anti‐ <scp>KIT</scp> Barzolvolimab for Chronic Spontaneous Urticaria
Allergy 2025cited by 24position: middledoi
Unmet needs in hereditary angioedema: an international survey of physicians
Orphanet Journal of Rare Diseases 2025cited by 8position: middledoi
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Journal of Allergy and Clinical Immunology 2025cited by 6position: middledoi
Sex matters in <scp>CSU</scp> : Women face greater burden and poorer urticaria control, especially in midlife— <scp>CURE</scp> insights
Journal of the European Academy of Dermatology and Venereology 2025cited by 5position: middledoi
No allergy, but mast cells are involved: <scp>MRGPRX2</scp> in chronic inflammatory skin diseases
Journal of the European Academy of Dermatology and Venereology 2025cited by 5position: firstdoi
Evaluation of routine care of prurigo nodularis in Germany: retrospective chart review study (ADVANCE PN)
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2025cited by 4position: middledoi
Safety and efficacy of barzolvolimab, an anti–KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study
Journal of the American Academy of Dermatology 2025cited by 3position: firstdoi
Nemolizumab in prurigo nodularis up to 100 weeks: <scp>OLYMPIA LTE</scp> interim analysis
Journal of the European Academy of Dermatology and Venereology 2025cited by 3position: middledoi
Patients with acute and chronic spontaneous urticaria have similar autoantibody profiles: CHAPEAU pilot study
British Journal of Dermatology 2025cited by 3position: middledoi
Improvement of Prurigo Nodularis With Erenumab
JAMA Dermatology 2025cited by 3position: lastdoi
Validation of the Urticaria Activity Score for Cold Urticaria
The Journal of Allergy and Clinical Immunology In Practice 2025cited by 3position: middledoi
Key Predictors of Adherence to a Mobile Health App for Managing Chronic Spontaneous Urticaria
Clinical and Translational Allergy 2025cited by 2position: middledoi
Can Synthetic Data Allow for Smaller Sample Sizes in Chronic Urticaria Research?
Clinical and Translational Allergy 2025cited by 2position: lastdoi
The Prurigo Control Test reflects the severity of itch and skin lesions in patients with chronic prurigo: Data from a real‐world study
Journal of the European Academy of Dermatology and Venereology 2025cited by 1position: middledoi
62278 Effect of Remibrutinib on Sleep and Daily Activities in Patients With Chronic Spontaneous Urticaria (CSU) up to Week 52 in the REMIX-1/-2 studies
Journal of the American Academy of Dermatology 2025cited by 1position: lastdoi
The Role of Mast Cells in the Pathophysiology of Chronic Prurigo
Journal of Investigative Dermatology 2025cited by 1position: lastdoi
Chronic Spontaneous Urticaria
JAMA 2024cited by 90position: middledoi
Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists
Journal of Allergy and Clinical Immunology 2024cited by 62position: middledoi
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis
JAMA Dermatology 2024cited by 46position: middledoi
Disease modification in chronic spontaneous urticaria
Allergy 2024cited by 43position: lastdoi
CRUSE<sup>®</sup>—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
Clinical and Translational Allergy 2024cited by 34position: middledoi
Cutaneous Components Leading to Pruritus, Pain, and Neurosensitivity in Atopic Dermatitis: A Narrative Review
Dermatology and Therapy 2024cited by 27position: middledoi
Mortality in adult patients with chronic spontaneous urticaria: A real-world cohort study
Journal of Allergy and Clinical Immunology 2024cited by 18position: middledoi
EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions
Journal of the European Academy of Dermatology and Venereology 2024cited by 13position: middledoi
An emerging aeroallergen in Europe: Tree-of-Heaven (Ailanthus altissima [Mill.] Swingle) inventory and pollen concentrations – Taking a metropolitan region in Germany as an example
The Science of The Total Environment 2024cited by 12position: middledoi
Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo
JAMA Dermatology 2024cited by 10position: firstdoi
Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A <scp>CRUSE</scp> ® mobile health study
Allergy 2024cited by 10position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marcus Maurer · McGill University71 papers (2012–2025)Petra Staubach · Johannes Gutenberg University Mainz30 papers (2012–2023)Karsten Weller · Humboldt-Universität zu Berlin27 papers (2012–2025)Pavel Kolkhir · Humboldt-Universität zu Berlin26 papers (2019–2025)Tomasz Hawro · Universitäres Kinderwunschzentrum Lübeck23 papers (2014–2024)Sabine Altrichter · Johannes Kepler University of Linz15 papers (2019–2025)Karoline Krause · Fraunhofer Institute for Translational Medicine and Pharmacology12 papers (2012–2024)Sonja Ständer · 4814912 papers (2017–2025)Markus Magerl · Humboldt-Universität zu Berlin11 papers (2012–2024)Jörg Scheffel · Humboldt-Universität zu Berlin10 papers (2019–2024)Frank Siebenhaar · Humboldt-Universität zu Berlin10 papers (2019–2024)Torsten Zuberbier · Berlin Institute of Health at Charité - Universitätsmedizin Berlin9 papers (2016–2023)Gordon Sussman · University of Toronto9 papers (2016–2025)Hanna Bonnekoh · Humboldt-Universität zu Berlin9 papers (2018–2025)Emek Kocatürk · Bahçeşehir University8 papers (2016–2025)Martin K. Church · Humboldt-Universität zu Berlin8 papers (2013–2023)Dorothea Terhorst‐Molawi · Fraunhofer Institute for Translational Medicine and Pharmacology7 papers (2021–2025) · 7 papers (2017–2023)Stefan Frischbutter · Humboldt-Universität zu Berlin7 papers (2019–2024)Ana M. Giménez‐Arnau · Johannes Gutenberg University Mainz7 papers (2016–2025)